OBJECTIVE: Inflammation is closely linked to angiogenesis, and Toll-like receptors (TLRs) are the key mediators of inflammatory responses. However, the impact of TLRs on angiogenesis is incompletely understood. In this study, we determined the involvement of TLRs in angiogenesis. METHODS AND RESULTS: In a mouse model of alkali-induced corneal neovascularization (CNV), we found that CNV was attenuated in TLR4-/- but not TLR2-/- mice. Further study revealed that the absence of TLR4 led to decreased production of proangiogenic factors in association with reduced accumulation of macrophages at the site of wounds, which was associated with reduced expression of high-mobility group box-1 (HMGB1) protein, an endogenous ligand for TLR4. Topical application of HMGB1 to the injured cornea promoted CNV with increased macrophage accumulation in wild-type mice but not in TLR4-/- mice. HMGB1 treatment in vitro also promoted the production of proangiogenic factors by mouse macrophages in a TLR4-dependent manner. Furthermore, antagonists of HMGB1 and TLR4 reduced CNV and macrophage recruitment in the injured cornea of wild-type mice. CONCLUSIONS: Our results suggest that the release of HMGB1 in the wounds initiates TLR4-dependent responses that contribute to neovascularization. Thus, targeting HMGB1-TLR4 signaling cascade may constitute a novel therapeutic approach to angiogenesis-related diseases.
OBJECTIVE:Inflammation is closely linked to angiogenesis, and Toll-like receptors (TLRs) are the key mediators of inflammatory responses. However, the impact of TLRs on angiogenesis is incompletely understood. In this study, we determined the involvement of TLRs in angiogenesis. METHODS AND RESULTS: In a mouse model of alkali-induced corneal neovascularization (CNV), we found that CNV was attenuated in TLR4-/- but not TLR2-/- mice. Further study revealed that the absence of TLR4 led to decreased production of proangiogenic factors in association with reduced accumulation of macrophages at the site of wounds, which was associated with reduced expression of high-mobility group box-1 (HMGB1) protein, an endogenous ligand for TLR4. Topical application of HMGB1 to the injured cornea promoted CNV with increased macrophage accumulation in wild-type mice but not in TLR4-/- mice. HMGB1 treatment in vitro also promoted the production of proangiogenic factors by mouse macrophages in a TLR4-dependent manner. Furthermore, antagonists of HMGB1 and TLR4 reduced CNV and macrophage recruitment in the injured cornea of wild-type mice. CONCLUSIONS: Our results suggest that the release of HMGB1 in the wounds initiates TLR4-dependent responses that contribute to neovascularization. Thus, targeting HMGB1-TLR4 signaling cascade may constitute a novel therapeutic approach to angiogenesis-related diseases.
Authors: Kumaravelu Jagavelu; Chittaranjan Routray; Uday Shergill; Steven P O'Hara; William Faubion; Vijay H Shah Journal: Hepatology Date: 2010-08 Impact factor: 17.425
Authors: Angela C Johnson; Fred P Heinzel; Eugenia Diaconu; Yan Sun; Amy G Hise; Douglas Golenbock; Jonathan H Lass; Eric Pearlman Journal: Invest Ophthalmol Vis Sci Date: 2005-02 Impact factor: 4.799
Authors: Diego G Espinosa-Heidmann; Ivan J Suner; Eleut P Hernandez; Dagoberto Monroy; Karl G Csaky; Scott W Cousins Journal: Invest Ophthalmol Vis Sci Date: 2003-08 Impact factor: 4.799
Authors: Claus Cursiefen; Lu Chen; Leonardo P Borges; David Jackson; Jingtai Cao; Czeslaw Radziejewski; Patricia A D'Amore; M Reza Dana; Stanley J Wiegand; J Wayne Streilein Journal: J Clin Invest Date: 2004-04 Impact factor: 14.808
Authors: David J Kaczorowski; Atsunori Nakao; Raghuveer Vallabhaneni; Kevin P Mollen; Ryujiro Sugimoto; Junichi Kohmoto; Brian S Zuckerbraun; Kenneth R McCurry; Timothy R Billiar Journal: Transplantation Date: 2009-05-27 Impact factor: 4.939
Authors: Allan Tsung; Rohit Sahai; Hiroyuki Tanaka; Atsunori Nakao; Mitchell P Fink; Michael T Lotze; Huan Yang; Jianhua Li; Kevin J Tracey; David A Geller; Timothy R Billiar Journal: J Exp Med Date: 2005-03-28 Impact factor: 14.307
Authors: Vilma Urbonaviciute; Barbara G Fürnrohr; Silke Meister; Luis Munoz; Petra Heyder; Francesco De Marchis; Marco E Bianchi; Carsten Kirschning; Hermann Wagner; Angelo A Manfredi; Joachim R Kalden; Georg Schett; Patrizia Rovere-Querini; Martin Herrmann; Reinhard E Voll Journal: J Exp Med Date: 2008-12-08 Impact factor: 14.307
Authors: Hatem A Elshabrawy; Abdul E Essani; Zoltán Szekanecz; David A Fox; Shiva Shahrara Journal: Autoimmun Rev Date: 2016-12-15 Impact factor: 9.754
Authors: Qing Lin; Chunling Fan; John T Skinner; Elizabeth N Hunter; Andrew A Macdonald; Peter B Illei; Kazuyo Yamaji-Kegan; Roger A Johns Journal: J Immunol Date: 2019-10-14 Impact factor: 5.422
Authors: Heidi E Lilja; Wayne A Morrison; Xiao-Lian Han; Jason Palmer; Caroline Taylor; Richard Tee; Andreas Möller; Erik W Thompson; Keren M Abberton Journal: Stem Cells Dev Date: 2013-01-29 Impact factor: 3.272
Authors: Buddy A Whitman; Darin J Knapp; David F Werner; Fulton T Crews; George R Breese Journal: Alcohol Clin Exp Res Date: 2013-07-29 Impact factor: 3.455